As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to EMA in 2020 about The use of rSDV and the recent guidance on the management of clinical trials during the COVID-19 pandemic (15/09/20) can be found below.